Unlocking the Potential of Binding Corporate Rules (BCRs) in Health Data Transfers
Marcelo Corrales Compagnucci, Mark Fenwick, Helena Haapio

TL;DR
This paper examines the role of Binding Corporate Rules (BCRs) in enabling secure, compliant health data transfers within corporate groups under GDPR, emphasizing their importance for trustworthy AI and international data protection.
Contribution
It provides a comprehensive analysis of BCRs in health data transfers, highlighting recent regulatory updates, approval processes, and the integration of international standards for AI governance.
Findings
BCRs are vital for compliant health data transfer within GDPR frameworks.
Streamlining BCR approval processes can boost adoption and compliance.
International standards enhance BCR development for trustworthy AI deployment.
Abstract
This chapter explores the essential role of Binding Corporate Rules (BCRs) in managing and facilitating secure health data transfers within corporate groups under the EU General Data Protection Regulation (GDPR). BCRs are tailored to ensure compliance with the GDPR and similar international data protection laws, presenting a flexible mechanism for transferring sensitive health and genomic data. The chapter situates BCRs within the broader spectrum of the GDPR international data transfer mechanisms, addressing the unique challenges posed by the sensitive nature of health data and the increased adoption of AI technologies. The European Data Protection Board (EDPB) Recommendations 1/2022 on BCRs, issued following the Schrems II decision, are critically analyzed, highlighting their stringent requirements and the need for a balanced approach that prioritizes data protection and an AI…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHealth Systems, Economic Evaluations, Quality of Life · Biomedical Ethics and Regulation · Pharmaceutical Economics and Policy
